Journal of Public Health and Primary Care

REVIEW ARTICLE
Year
: 2021  |  Volume : 2  |  Issue : 2  |  Page : 32--37

Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges


Sweety Sharma1, Bhawna Sharma2 
1 Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
2 Department of Nursing, Rajkumari Amrit Kaur College of Nursing, Delhi, India

Correspondence Address:
Dr. Sweety Sharma
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi
India

Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type ATTR. Previously, no treatment is available, due to which liver transplantation, multi-organ transplantation, and symptomatic treatment were the only therapies at that time. Approval of Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules in 2019, acts like a kick in the research fields due to which other therapeutics are now emerging. Several clinical trials are going on to evaluate the efficacy of different drugs in ATTR-CM. Most of the clinical trials demonstrated positive outcomes which leads to further evaluation for confirmation. In this review treatment pipeline, ongoing clinical trials and challenges related to ATTR-CM are described.


How to cite this article:
Sharma S, Sharma B. Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges.J Public Health Prim Care 2021;2:32-37


How to cite this URL:
Sharma S, Sharma B. Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges. J Public Health Prim Care [serial online] 2021 [cited 2021 Nov 29 ];2:32-37
Available from: http://www.jphpc.com/article.asp?issn=2772-3666;year=2021;volume=2;issue=2;spage=32;epage=37;aulast=Sharma;type=0